



Merseyside Inter Agency Drug Misuse Database

Wirral DAAT

Quarter 4 2007/08

**Lloyd Baron, Martin Chandler,
Jim McVeigh**

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531

m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521

L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Syringe Exchange Services	5
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 13: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
Pharmacy	10
Table 14: Individuals by Gender	
Table 15: Individuals by Age Group	
Table 16: Year to Date, by Gender & Age Group	
Combined	11
Table 17: Individuals in Syringe Exchange, by Gender	
Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 19: Individuals in Syringe Exchange, by Age Group	
Table 20: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 21: Year to Date, by Gender & Age Group	
Table 22: Total Syringes Provided	

National Drug Treatment Monitoring System (NDTMS) 13

Table 23: Individuals in contact with Treatment Services, by Gender

Table 24: Year to Date, by Gender

Table 25: Individuals in contact with Treatment Services, by Age Group

Table 26: Year to Date, by Age Group

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Table 28: Individuals in contact with Treatment Services, by Main Drug of Use

Connexions 16

Table 29: Individuals in Contact with Connexions, by Gender

Table 30: Year to Date, by Gender

Table 31: Individuals in Contact with Connexions, by Age

Table 32: Year to Date, by Age

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 34: Year to Date, by Drug/Alcohol Problem

Combined Datasets 18

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 36: Year to Date, by Gender & Age Group

Cross Matched Datasets 19

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.


To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)**Quarter 4 (2007/08)****Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	165	87.8
Female	23	12.2
Age Group		
Under 18	0	0.0
18-19	12	6.4
20-24	43	22.9
25-29	36	19.1
30-34	31	16.5
35-39	34	18.1
40-44	19	10.1
45+	13	6.9
Total	188	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0.0	1	1.1	1	>1
18-19	44	8.3	1	1.1	45	7.2
20-24	134	25.3	13	13.7	147	23.5
25-29	94	17.7	12	12.6	106	17.0
30-34	68	12.8	24	25.3	92	14.7
35-39	92	17.4	19	20.0	111	17.8
40-44	66	12.5	21	22.1	87	13.9
45+	32	6.0	4	4.2	36	5.8
Total	530	100	95	100	625	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	2
Benzodiazepines	3	5
Cannabis	34	11
Crack	34	24
Cocaine	8	44
Ecstasy	0	5
Heroin	49	22
Methadone	2	3
Subutex	0	1

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

SYRINGE EXCHANGE SERVICES

Quarter 4 (2007/08)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	109	98.2
Female	2	1.8
<i>Total</i>	<i>111</i>	<i>100</i>
All Clients		
Male	372	94.2
Female	23	5.8
<i>Total</i>	<i>395</i>	<i>100</i>

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	33	94.3
Female	2	5.7
<i>Total</i>	<i>35</i>	<i>100</i>
All Clients		
Male	160	87.9
Female	22	12.1
<i>Total</i>	<i>182</i>	<i>100</i>

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	>1	1	>1
18-19	13	11.7	18	4.6
20-24	37	33.3	79	20.0
25-29	13	11.7	55	13.9
30-34	16	14.4	63	15.9
35-39	22	19.8	86	21.8
40-44	1	>1	45	11.4
45+	8	7.2	48	12.2
Total	111	100	395	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	2.9	1	>1
20-24	4	11.4	6	3.3
25-29	4	11.4	13	7.1
30-34	3	8.6	26	14.3
35-39	18	51.4	69	37.9
40-44	0	0.0	32	17.6
45+	5	14.3	35	19.2
Total	35	100	182	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	1	>1	0	0.0
18-19	18	4.8	0	0.0
20-24	78	21.0	1	4.3
25-29	53	14.2	2	8.7
30-34	56	15.1	7	30.4
35-39	79	21.2	7	30.4
40-44	41	11.0	4	17.4
45+	46	12.4	2	8.7
Total	372	100	23	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	>1	0	0.0
20-24	5	3.1	1	4.5
25-29	11	6.9	2	9.1
30-34	19	11.9	7	31.8
35-39	63	39.4	6	27.3
40-44	28	17.5	4	18.2
45+	33	20.6	2	9.1
Total	160	100	22	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	6	<1	1	1.9	7	<1
18-19	41	5.2	0	0.0	41	4.8
20-24	163	20.6	1	1.9	164	19.4
25-29	127	16.0	3	5.7	130	15.4
30-34	123	15.5	13	24.5	136	16.1
35-39	153	19.3	20	37.7	173	20.4
40-44	100	12.6	8	15.1	108	12.8
45+	80	10.1	7	13.2	87	10.3
Total	793	100	53	100	846	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	<1	1	2.0	2	<1
18-19	6	1.7	0	0.0	6	1.5
20-24	23	6.3	1	2.0	24	5.8
25-29	36	9.9	3	6.1	39	9.5
30-34	52	14.3	12	24.5	64	15.5
35-39	117	32.2	17	34.7	134	32.5
40-44	69	19.0	8	16.3	77	18.7
45+	59	16.3	7	14.3	66	16.0
Total	363	100	49	100	412	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	1	>1	0	0.0
Crack	0	0.0	0	0.0
Heroin	16	14.7	2	100
Methadone	0	0.0	0	0.0
Steroids	76	69.7	0	0.0
Other	16	14.7	0	0.0
Total	109	100	2	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta- mine		Benzodi- azepine		Cocaine		Crack		Heroin		Methadone		Steroids		
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Under 18	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1.0
18-19	-	-	-	-	-	-	-	-	1	6.0	-	-	12	16.0	
20-24	-	-	-	-	-	-	-	-	2	11.0	-	-	33	43.0	
25-29	-	-	-	-	-	-	-	-	4	22.0	-	-	9	12.0	
30-34	-	-	-	-	1	100	-	-	1	6.0	-	-	13	17.0	
35-39	-	-	-	-	-	-	-	-	8	44.0	-	-	4	5.0	
40-44	-	-	-	-	-	-	-	-	-	-	-	-	1	1.0	
45+	-	-	-	-	-	-	-	-	2	11.0	-	-	3	4.0	
Total*	-	-	-	-	1	100	-	-	18	100	-	-	76	100	

* % Totals are by Drug, not Age Group

PHARMACY SYRINGE EXCHANGE

Table 14: Individuals by Gender

New Clients	n	%
Male	41	85.4
Female	7	14.6
<i>Total</i>	<i>48</i>	<i>100</i>
All Clients		
Male	134	83.8
Female	26	16.3
<i>Total</i>	<i>160</i>	<i>100</i>

Table 15: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	5	10.4	9	5.6
25-29	4	8.3	11	6.9
30-34	13	27.1	29	18.1
35-39	7	14.6	32	20.0
40-44	13	27.1	49	30.6
45+	6	12.5	30	18.8
<i>Total</i>	<i>48</i>	<i>100</i>	<i>160</i>	<i>100</i>

Table 16: Year to Date, by Gender & Age Group

Age Group	Gender				<i>Total in Age Group</i>	
	Male		Female			
	n	%	n	%	<i>n</i>	<i>%</i>
Under 18	0	0.0	0	0.0	<i>0</i>	<i>0.0</i>
18-19	0	0.0	0	0.0	<i>0</i>	<i>0.0</i>
20-24	21	8.2	1	2.2	<i>22</i>	<i>7.3</i>
25-29	29	11.3	3	6.5	<i>32</i>	<i>10.6</i>
30-34	41	16.0	13	28.3	<i>54</i>	<i>17.8</i>
35-39	57	22.2	11	23.9	<i>68</i>	<i>22.4</i>
40-44	66	25.7	14	30.4	<i>80</i>	<i>26.4</i>
45+	43	16.7	4	8.7	<i>47</i>	<i>15.5</i>
<i>Total</i>	<i>257</i>	<i>100</i>	<i>46</i>	<i>100</i>	<i>303</i>	<i>100</i>

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 17: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	146	95.4
Female	7	4.6
<i>Total</i>	<i>153</i>	<i>100</i>
All Clients		
Male	486	91.2
Female	47	8.8
<i>Total</i>	<i>533</i>	<i>100</i>

Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	70	90.9
Female	7	9.1
<i>Total</i>	<i>77</i>	<i>100</i>
All Clients		
Male	274	85.6
Female	46	14.4
<i>Total</i>	<i>320</i>	<i>100</i>

Table 19: Individuals in Syringe Exchange, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	1	>1	1	>1
18-19	13	8.5	18	3.4
20-24	42	27.5	88	16.5
25-29	17	11.1	66	12.4
30-34	27	17.6	88	16.5
35-39	27	17.6	112	21.0
40-44	13	8.5	86	16.1
45+	13	8.5	74	13.9
<i>Total</i>	<i>153</i>	<i>100</i>	<i>533</i>	<i>100</i>

Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	1.3	1	>1
20-24	9	11.7	15	4.7
25-29	8	10.4	24	7.5
30-34	14	18.2	51	15.9
35-39	23	29.9	95	29.7
40-44	12	15.6	73	22.8
45+	10	13.0	61	19.1
Total	77	100	320	100

Table 21: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	6	>1	1	1.1	7	>1
18-19	41	4.2	0	0.0	41	3.8
20-24	179	18.3	2	2.2	181	16.9
25-29	154	15.7	6	6.5	160	14.9
30-34	152	15.5	25	26.9	177	16.5
35-39	189	19.3	28	30.1	217	20.2
40-44	144	14.7	20	21.5	164	15.3
45+	114	11.6	11	11.8	125	11.7
Total	979	100	93	100	1072	100

Table 22: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	30,605	8,480	39,085	130,740

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2007/08)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 23: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	181	79.1
Female	48	20.9
<i>Total</i>	<i>229</i>	<i>100</i>
All Clients		
Male	2132	73.4
Female	771	26.6
<i>Total</i>	<i>2903</i>	<i>100</i>

Table 24: Year to Date, by Gender

New Clients	n	%
Male	563	75.0
Female	188	25.0
<i>Total</i>	<i>751</i>	<i>100</i>
All Clients		
Male	2299	73.5
Female	830	26.5
<i>Total</i>	<i>3129</i>	<i>100</i>

Table 25: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	26	11.4	84	2.9
18-19	17	7.4	80	2.8
20-24	29	12.7	189	6.5
25-29	33	14.4	264	9.1
30-34	32	13.9	381	13.1
35-39	45	20.0	717	24.7
40-44	31	13.5	715	24.6
45+	16	7.0	473	16.3
Total	229	100	2903	100

Table 26: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	77	10.3	178	5.7
18-19	42	5.6	109	3.5
20-24	86	11.5	346	11.1
25-29	99	13.2	531	17.0
30-34	113	15.0	705	22.5
35-39	156	20.8	688	22.0
40-44	119	15.8	382	12.2
45+	59	7.9	190	6.1
Total	751	100	3129	100

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	227	99.1	2871	98.9
White Irish	1	>1	8	>1
Other White	0	0.0	3	>1
White & Black Caribbean	0	0.0	5	>1
White & Black African	0	0.0	4	>1
Other Mixed	0	0.0	2	>1
Other Asian	0	0.0	4	>1
African	0	0.0	1	>1
Other Black	0	0.0	1	>1
Other	1	>1	2	>1
Unknown	0	0.0	2	>1
Total	229	100	2903	100

Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	106	46.3	1909	65.8
Methadone	8	3.5	118	4.1
Other Opiates	1	>1	87	3.0
Benzodiazepine	1	>1	12	>1
Amphetamines	7	3.1	67	2.3
Cocaine	40	17.5	282	9.7
Crack	18	7.9	137	4.7
Ecstasy	2	>1	16	>1
Cannabis	37	16.2	237	8.2
Other/Unknown	9	4.0	38	1.0
Total	229	100	2903	100

CONNEXIONS

Quarter 4 (2007/08)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 29: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	81	34.7
Female	43	65.3
Total	124	100

Table 30: Year to Date, by Gender

Gender	n	%
Male	136	68.0
Female	64	32.0
Total	200	100

Table 31: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	36	29.0
17	34	27.4
18	28	22.6
19	26	21.0
Total	124	100.0

Table 32: Year to Date, by Age

Age Group	n	%
16	51	25.5
17	53	26.5
18	48	24.0
19	48	24.0
Total	200	100

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	80	35.5
Drugs	44	64.5
Total	124	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 34: Year to Date, by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	69	34.5
Drugs	131	65.5
Total	200	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS

Quarter 4 (2007/08)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	2639	76.0
Female	832	24.0
Age Group		
Under 18	180	5.2
18-19	178	5.1
20-24	436	12.6
25-29	558	16.1
30-34	699	20.1
35-39	739	21.3
40-44	431	12.4
45+	250	7.2
Total	3471	100

Table 36: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	166	4.8	62	6.4	228	5.1
18-19	204	5.9	53	5.5	257	5.8
20-24	449	12.9	53	5.5	502	11.3
25-29	413	11.9	99	10.2	512	11.5
30-34	445	12.8	147	15.2	592	13.3
35-39	685	19.7	257	26.5	942	21.2
40-44	672	19.3	190	19.6	862	19.4
45+	443	12.7	108	11.1	551	12.4
Total	3477	100	969	100	4446	100

CROSS-MATCHED DATASETS

Quarter 4 (2007/08)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets




Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

